Loading news...
Hennion and Walsh Asset Management Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 53.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,047 shares of the biopharmaceutical company's stock after selling 1,206 shares during the period. Hennion and
Cerity Partners LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 48.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 20,534 shares of the biopharmaceutical company's stock after acquiring an additional 6,676 shares during the period. Cerity Partners LLC's holdings in Regeneron
Regeneron (REGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Clear Harbor Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 26.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,637 shares of the biopharmaceutical company's stock after purchasing
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) after a surprising shift in analyst sentiment?
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been upgraded by Bank of America, which raised its rating on the biotechnology company to ‘Buy' from ‘Underperform' and increased its price objective to $860 from $627, citing improving fundamentals across key products and multiple potential catalysts in 2026. Shares of Regeneron traded up 3.5% at about $803 on Wednesday afternoon.
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
M2i Global Inc (OTC:MTWO), along with Volato Group which is in the process of merging with the company, announced a strategic collaboration with Titanium X...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been upgraded by Bank of America, which raised its rating on the biotechnology company to ‘Buy’ from...
Reconnaissance Energy Africa Ltd (TSX-V:RECO, OTCQX:RECAF) has upsized its earlier private placement annoucement of C$20M to C$32M to fund a broad 2026...
Merit Financial Group LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 302.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,859 shares of the biopharmaceutical company's stock after purchasing an additional 1,397 shares during the period. Merit Financial Group LLC's
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) CEO Paul McGlone talked with Proactive's Stephen Gunnion about the company’s latest announcement regarding an...
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
Ascent Group LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 56.0% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 581 shares of the biopharmaceutical company's stock after selling 738 shares during the quarter.
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.